Effect of MN-166 (ibudilast) on acute respiratory failure prevention in hospitalized participants with COVID-19: a randomized, double-blind, placebo-controlled phase 2 study.

BMC Pulm Med · 2026 · PMC13170009 · PMID 41928198

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

All-cause mortality was lower in the MN-166 group compared to the placebo, where 2 (11.8%) participants died from severe COVID-19 complications within 60 days in placebo group and none in MN-166 group though this difference did not reach statistical significance.

also in 111,027 other papers

a positive trendno p-value reported

A positive trend was observed in the mean MIF changes from baseline within the MN-166 treatment group, with P values ranging from 0.03 to 0.09.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.